Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.11 USD | -1.45% | +2.35% | -10.54% |
May. 16 | AxoGen Initiates Rolling Submission to FDA For Avance Nerve Graft | MT |
May. 02 | Transcript : AxoGen, Inc., Q1 2024 Earnings Call, May 02, 2024 |
Financials (USD)
Sales 2024 * | 179M | Sales 2025 * | 202M | Capitalization | 267M |
---|---|---|---|---|---|
Net income 2024 * | -18M | Net income 2025 * | - | EV / Sales 2024 * | 1.49 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.33 x |
P/E ratio 2024 * |
-14.8
x | P/E ratio 2025 * |
-458
x | Employees | 427 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.22% |
Latest transcript on AxoGen, Inc.
1 day | -1.45% | ||
1 week | +2.35% | ||
Current month | -4.68% | ||
1 month | -12.34% | ||
3 months | -41.08% | ||
6 months | +3.56% | ||
Current year | -10.54% |
Managers | Title | Age | Since |
---|---|---|---|
Karen Zaderej
CEO | Chief Executive Officer | 62 | 06-04-30 |
Nir Naor
DFI | Director of Finance/CFO | 50 | Dec. 05 |
Marc Began
CMP | Compliance Officer | 57 | 23-03-05 |
Members of the board | Title | Age | Since |
---|---|---|---|
Paul Thomas
BRD | Director/Board Member | 68 | 20-09-29 |
Director/Board Member | 63 | 16-08-31 | |
John Johnson
BRD | Director/Board Member | 66 | 21-07-18 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 430 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-23 | 6.11 | -1.45% | 516,883 |
24-05-22 | 6.2 | +1.81% | 262,505 |
24-05-21 | 6.09 | -1.77% | 163,210 |
24-05-20 | 6.2 | +2.65% | 161,147 |
24-05-17 | 6.04 | +1.17% | 210,247 |
Delayed Quote Nasdaq, May 23, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.54% | 267M | |
+10.22% | 223B | |
+12.99% | 194B | |
+18.09% | 141B | |
+28.66% | 109B | |
+2.09% | 64.85B | |
+14.70% | 52.7B | |
+6.68% | 51.77B | |
+8.29% | 44.12B | |
+2.60% | 36.21B |
- Stock Market
- Equities
- AXGN Stock